Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Single Blinded Study of the Safety and Immunogenicity of Pentavalent DTaP-Hep B-IPV Combination Vaccine (Pediarix; GlaxoSmithKline (GSK) Biologicals) Administered to Healthy Neonates and Infants at Birth, 2, and 6 Months of Age Compared to a Routine Infant Schedule at 2, 4, and 6 Months of Age.

Next Previous
X
Search
Trial Profile

Randomized, Single Blinded Study of the Safety and Immunogenicity of Pentavalent DTaP-Hep B-IPV Combination Vaccine (Pediarix; GlaxoSmithKline (GSK) Biologicals) Administered to Healthy Neonates and Infants at Birth, 2, and 6 Months of Age Compared to a Routine Infant Schedule at 2, 4, and 6 Months of Age.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hepatitis B vaccine recombinant
  • Indications Diphtheria; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics

    • Most Recent Events

    • 22 Sep 2009 Planned number of patients changed from 205 to 5 as reported by ClinicalTrials.gov.
    • 23 Oct 2008 Planned end date changed from 1 Mar 2008 to 1 Aug 2006 as reported by ClinicalTrials.gov.
    • 23 Oct 2008 Actual start date changed from Oct 2005 to Dec 2005 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top